Panel |
---|
|
1: This is an example of a blinded study using double dummy packaging. Are these types of studies done? 2. The Weights are made up- we need team help in providing real weight amounts. 3. The strength of the cartridge- WE see these like Joules says 5% , while other use mg/ML. What should be used, as a measure of the strength. |
In this study, subjects were randomized were randomized to either nicotine replacement patches or ENDsENDS devices using e-nicotine liquid cartridges. In order to maintain the blind, subjects used both the nicotine replacement patches and the ENDS devicedevices. Subjects were requested not to smoke, but the number of regular cigarettes used were collected. Subject were seen every day for 15 days, . The nicotine patch was applied at , at rotating sites, and the ENDS nicotine cartridge was replaced every day. The cartridge was weight weighed when dispended dispensed and upon return. On days, 1, 5, and 10 subjects remained in the clinic for 4 hours for collection of biomarkers. On these days, a new ENDS nicotine cartridge device was inserted and then used for 10 puffs were taken over 10 minutes, and then not used for 4 hoursthe remaining collection period. A new cartridge was insert inserted at the end of the 4 hours. The -hour collection period. A nicotine replacement patch was applied prior to using the ENDS device on these days.
The SU domain was used to represent the number of cigarettes used, but is not shown.
In this study, the weight of the contents in the cartridges were being accounted for, as well as the number of patches. A Product Accountability (DA) domain was submitted cartridge was tracked. The DA domain was used to represent dispensed and returned amounts. Each cartridge had a uniquely assigned number. The sponsor used DAREFID that appeared on the label to identify the cartridge. Multiple cartridges were dispensed at weekly visits, but each cartridge was tracked. At each weekly visit, all previously dispended cartridges were returned, and new cartridges dispensed. Cartridges were replaced at each visit. DADTC are the visit dates when the cartridge was returned or dispensed. A returned cartridges that was not used was recorded as having weight of the dispensed cartridges, NOTE ; A REAL EXAMPLE FROM A SPONOSR WOULD BE HELPFUL. THESE ARE MADE UP AMOUNTS. NEED TO ENSURE EXPOSURE NUMBERS MATCH THESE WEIGHTS:weights of each cartridge. Only a few rows are shown. The product accountability information was not provided for the nicotine replacement patches.
Dataset wrap |
---|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | DASEQ | DAREFID | DATESTCD | DATEST | DACAT | DASCAT | DAORRES | DAORRESU | DASTRESC | DASTRESN | DASTRESU | DASTAT | DAREASND | VISITNUM | DADTC |
---|
1 | ABCTEDP07 | DA | ABC-0100110001 | | CRT8754 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.3 | g | 25 | 25 | g | 1 | 2004-06-2606 | 2 | ABCTEDP07 | DA | ABC-0100110001 | | CRT8768CRT8754 | DISPAMTRETAMT | Dispensed Returned Amount | STUDY PRODUCT | E-LIQUID | 2325 | g | 252325 | 23 | g | 1 | 20042020-06-2606 | 3 | ABCTEDP07 | DA | ABC-0100110001 | | CRT8769CRT9756 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.1 | g | 25 | 25 | g | 1 | 20042020-06-2607 | 4 | ABCTEDP07 | DA | ABC-0100110001 | | CRT8754CRT9756 | RETAMT | Returned Amount | STUDY PRODUCT | NOT DONE | Subject forgot to return the cartridge | 2020-07-06 | E-LIQUID | 10 | g | 14 | 14 | 5 | ABC | DA | ABC-01001 | | CRT8768 | RETAMT | Returned Amount | STUDY PRODUCT | 24 | g | 24 | 24 | g | 2 | 2020-07-06 | 6 | ABC | DA | ABC-01001 | | CRT8769 | RETAMT | Returned Amount | STUDY PRODUCT | 10 | g | 10 | 10 | -08 | 5 | TEDP07 | DA | 10001 | | CRT9955 | g | 2 | 2020-07-06 | 7 | ABC | DA | ABC-01001 | | CRT9756 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.2 | g g | 25 | 25 | g | 2 | 2020-072004-06 | 8 | ABC | DA | ABC-01001 | | CRT9756 | RETAMT | Returned Amount | STUDY PRODUCT | 14 | g | 14 | 143 | g | 3 | 2020-07-10 | 9 | ABC | DA | ABC-01001 | | CRT8754 | RETAMT | Returned Amount | STUDY PRODUCT | 10 | g | 10 | 10 | g | 3 | 2020-07-06 | -08 |
|
|
EC was used to represent the collected exposure data since a double dummy -blind design was used. The EX domain domain was used to represent the subject's exposure to the actual product containing nicotine. The applicant represented each cartridge and patch used. The dose was represented as "1" to indicate 1 cartridge or patch. The actual date and specific time of usage of the cartridge was recorded on days 1, 5, and 10, while only the date of usage was recorded on other days.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | ECSEQ | ECTRT | ECDOSE | ECDOSTXT | ECDOSU | ECDOSFRM | ECROUTE |
---|
ECFREQ | ECLOC | ECLAT | ECDIR | EPOCH | ECSTDTC | ECENDTC |
---|
1 | TEDP07 | EC | 10001 | 1 | ENDS |
---|
1CONTAINERINHALED | ONCE | TREATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06- | 01T801T:801T08:10 | 2 | TEDP07 | EC | 10001 | 2 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | ARM | RIGHT | UPPER |
---|
TREATMENTPRODUCT EXPOSURE | 2020-06-01 | 2020-06-02 | 3 | TEDP07 | EC | 10001 | 3 | ENDS |
---|
1CONTAINERINHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT01:T1201T12:10 | 2020-06-02 | 4 | TEDP07 | EC | 10001 |
---|
11CONTAINERINHALED | AD LIBITUM | TREATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-02 | 2020-06- | 021 PATCH PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | ARM | LEFT | UPPER | TREATMENTPRODUCT EXPOSURE | 2020-06-02 | 2020-06-03 | 6 | TEDP07 | EC | 10001 |
---|
21CONTAINERINHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT033 PATCH PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | LEFT | UPPER | TREATMENTPRODUCT EXPOSURE | 2020-06-03 | 2020-06-04 | 7 | TEDP07 | EC | 10001 |
---|
41CONTAINERINHALED | AD LIBITUM | TREATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-04 | 2020-06-05 | 8 | TEDP07 | EC | 10001 |
---|
5 PATCH PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | LEFT | LOWER | TREATMENTPRODUCT EXPOSURE | 2020-06-04 | 2020-06-05 | 9 | TEDP07 | EC | 10001 |
---|
61CONTAINERINHALED | ONCE | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENTT09;8T09;8711 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | RIGHT | LOWER | TREATMENTPRODUCT EXPOSURE | 2020-06-10 | 2020-06-11 | 11 | TEDP07 | EC | 10001 |
---|
81CONTAINERINHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT10:T12 |
|
TIME FORMATS NEED TO BE FIXED Subject 10001 was randomized to the 5% pharmaceutical strength of the nicotine e-liquid, and subject 20001 was randomized to the nicotine patch with a pharmaceutical strength of 14mg. The applicant only represented the active product exposure for each subject in EX.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | EXSEQ | EXTRT | EXDOSE | EXDOSU | EXDOSFRM | EXROUTE |
---|
EXFREQ | EXLOC | EXLAT | EXDIR | EPOCH | EXPSTRG | EXPSTRGU |
---|
ECSTDTCECENDTCEXENDTC |
---|
1 | TEDP07 | EX | 10001 | 1 | e nicotine liquid |
---|
3INHALED | ONCE | TREATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | 2020-06- | 01:T80101T:8:10 | 2 | TEDP07 | EX | 10001 | 2 | e nicotine liquid | 15.1 | g |
---|
INHALED | AD LIBITUM | TRE5ATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | 2020-06- | 01T8:10 | 2020-06-02 | 3 | TEDP07 | EX | 10001 | 3 | e nicotine liquid | 13 | g |
---|
INHALED | AD LIBITUM | | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | TREATMENT0203 | 4 | TEDP07 | EX | 10001 | 4 | e nicotine liquid | 12 | g |
---|
INHALED | AD LIBITUM | | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | TREATMENT0304 | 5 | TEDP07 | EX | 10001 | 5 | e nicotine liquid | 9 | g |
---|
INHALED | AD LIBITUM | | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | TREATMENT | 2020-06-04 | 2020-06-05 | 6 | TEDP07 | EX | 10001 | 6 | e nicotine liquid | 7 | g |
---|
INHALED | ONCE | | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | TREATMENT09T809T810T08:40 | 7 | TEDP07 | EX | 10001 | 7 | e nicotine liquid | 5 |
---|
mg | INHALED | AD LIBITUM | | g | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | TREATMENT10T:240EC10001 e liquid replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL | QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-01 | 2020-06-02 | 9 | TEDP07 |
---|
ECe liquid replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL | QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-02 | 2020-06-03 | 10 | TEDP07 |
---|
ECe liquid replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
QD | TREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-03 | 2020-06-04 | 11 | TEDP07 |
---|
EC e liquid replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL | QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-04 | 2020-06-05 | 12 | TEDP07 |
---|
ECe liquid replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL | QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-10 | 2020-06-11 |
|
|